New combo shows promise against tough skin cancer
NCT ID NCT05309421
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 30 times
Summary
This study tests a new drug, EVX-01, combined with the standard immunotherapy pembrolizumab in 17 adults with advanced melanoma that cannot be removed by surgery. The goal is to see if the combination shrinks tumors better than pembrolizumab alone. Participants have not received checkpoint inhibitor treatment before.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Divisione di Oncologia Medica del Melanoma
Milan, Italy
-
Instituto Nazionale Tumori IRCCS Fondazione
Naples, Italy
-
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2065, Australia
-
One Clinical Research
Nedlands, Western Australia, 6009, Australia
Conditions
Explore the condition pages connected to this study.